3WMK
 
 | |
4NHI
 | |
2PL2
 | | Crystal structure of TTC0263: a thermophilic TPR protein in Thermus thermophilus HB27 | | 分子名称: | Hypothetical conserved protein TTC0263 | | 著者 | Lim, H, Kim, K, Han, D, Oh, J. | | 登録日 | 2007-04-18 | | 公開日 | 2008-03-04 | | 最終更新日 | 2024-03-13 | | 実験手法 | X-RAY DIFFRACTION (2.5 Å) | | 主引用文献 | Crystal structure of TTC0263, a thermophilic TPR protein from Thermus thermophilus HB27.
Mol.Cell, 24, 2007
|
|
7BXA
 | | Crystal structure of PD-1 in complex with tislelizumab Fab | | 分子名称: | Programmed cell death protein 1, heavy chain, light chain | | 著者 | Heo, Y.S, Lee, S.H, Lim, H, Lee, H.T, Kim, Y.J, Park, E.B. | | 登録日 | 2020-04-18 | | 公開日 | 2020-06-10 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (3.32 Å) | | 主引用文献 | Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy.
Biochem.Biophys.Res.Commun., 527, 2020
|
|
2Q7F
 | |
3ZHL
 | |
3ZHK
 | |
3ZHD
 | |
5X8M
 | | PD-L1 in complex with durvalumab | | 分子名称: | Programmed cell death 1 ligand 1, durvalumab heavy chain, durvalumab light chain | | 著者 | Heo, Y.S, Lee, H.T. | | 登録日 | 2017-03-03 | | 公開日 | 2017-08-16 | | 実験手法 | X-RAY DIFFRACTION (2.661 Å) | | 主引用文献 | Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Sci Rep, 7, 2017
|
|
5X8L
 | | PD-L1 in complex with atezolizumab | | 分子名称: | Programmed cell death 1 ligand 1, atezolizumab heavy chain, atezolizumab light chain | | 著者 | Heo, Y.S, Lee, H.T. | | 登録日 | 2017-03-03 | | 公開日 | 2017-08-16 | | 実験手法 | X-RAY DIFFRACTION (3.1 Å) | | 主引用文献 | Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Sci Rep, 7, 2017
|
|
6B43
 | | CryoEM structure and atomic model of the Kaposi's sarcoma-associated herpesvirus capsid | | 分子名称: | Major capsid protein, Small capsomere-interacting protein, Triplex capsid protein 1, ... | | 著者 | Dai, X.H, Gong, D.Y, Sun, R, Zhou, Z.H. | | 登録日 | 2017-09-25 | | 公開日 | 2017-11-08 | | 最終更新日 | 2019-12-18 | | 実験手法 | ELECTRON MICROSCOPY (4.2 Å) | | 主引用文献 | Structure and mutagenesis reveal essential capsid protein interactions for KSHV replication.
Nature, 553, 2018
|
|
6MUJ
 | | Formylglycine generating enzyme bound to copper | | 分子名称: | 2,3-DIHYDROXY-1,4-DITHIOBUTANE, CALCIUM ION, COPPER (II) ION, ... | | 著者 | Lafrance-Vanasse, J, Appel, M.J, Tsai, C.-L, Bertozzi, C, Tainer, J.A. | | 登録日 | 2018-10-23 | | 公開日 | 2019-02-27 | | 最終更新日 | 2023-10-11 | | 実験手法 | X-RAY DIFFRACTION (2.249 Å) | | 主引用文献 | Formylglycine-generating enzyme binds substrate directly at a mononuclear Cu(I) center to initiate O2activation.
Proc. Natl. Acad. Sci. U.S.A., 116, 2019
|
|
5Y9J
 | | BAFF in complex with belimumab | | 分子名称: | Tumor necrosis factor ligand superfamily member 13B, belibumab light chain, belimumab heavy chain | | 著者 | Heo, Y.-S, Shin, W. | | 登録日 | 2017-08-25 | | 公開日 | 2018-02-21 | | 最終更新日 | 2019-09-04 | | 実験手法 | X-RAY DIFFRACTION (2.05 Å) | | 主引用文献 | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
Nat Commun, 9, 2018
|
|
5Y9K
 | | Structure of the belimumab Fab fragment | | 分子名称: | belimumab heavy chain, belimumab light chain | | 著者 | Heo, Y.-S, Shin, W. | | 登録日 | 2017-08-25 | | 公開日 | 2018-02-21 | | 最終更新日 | 2019-09-04 | | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | | 主引用文献 | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
Nat Commun, 9, 2018
|
|
5GGS
 | | PD-1 in complex with pembrolizumab Fab | | 分子名称: | Programmed cell death protein 1, heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (1.997 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGV
 | | CTLA-4 in complex with tremelimumab Fab | | 分子名称: | Cytotoxic T-lymphocyte protein 4, heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (1.998 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGT
 | | PD-L1 in complex with BMS-936559 Fab | | 分子名称: | IGK@ protein, IgG H chain, Programmed cell death 1 ligand 1 | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2024-03-20 | | 実験手法 | X-RAY DIFFRACTION (2.8 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGR
 | | PD-1 in complex with nivolumab Fab | | 分子名称: | Programmed cell death protein 1, heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (3.3 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGQ
 | | Crystal structure of Nivolumab Fab fragment | | 分子名称: | nivolumab heavy chain, nivolumab light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGU
 | | Crystal structure of tremelimumab Fab | | 分子名称: | heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (2.292 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
6JC2
 | | Crystal structure of the Fab fragment of ipilimumab | | 分子名称: | SULFATE ION, ipilimumab fab heavy chain, ipilimumab fab light chain | | 著者 | Heo, Y.S. | | 登録日 | 2019-01-27 | | 公開日 | 2019-09-11 | | 実験手法 | X-RAY DIFFRACTION (2.65 Å) | | 主引用文献 | Crystal Structure of the Fab Fragment of an Anti-CTLA-4 Antibody, Ipilimumab, Used for Cancer Immunotherapy
Bull.Korean Chem.Soc., 40, 2019
|
|
